Slingshot members are tracking this event:
Exelixis’ (EXEL) Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Slingshot Insights Explained
Sep 21, 2018
Don’t see a project related to the catalyst you care about?
Related Keywords Cabometyx, Cabozantinib, Hepatocellular Carcinoma